jounce.png
Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
25 nov. 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
16 nov. 2020 08h00 HE | Jounce Therapeutics, Inc.
-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce’s PD-1 inhibitor, JTX-4014- -On track to begin enrollment by year-end 2020- CAMBRIDGE, Mass., Nov. 16,...
jounce.png
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting
11 nov. 2020 08h00 HE | Jounce Therapeutics, Inc.
-Preclinical data highlight Jounce’s approach to identify potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064- -Enrollment in Phase 1 monotherapy...
jounce.png
Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
09 nov. 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Reports Third Quarter 2020 Financial Results
06 nov. 2020 07h00 HE | Jounce Therapeutics, Inc.
-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT...
jounce.png
Jounce Therapeutics Announces Update on Vopratelimab Program
02 nov. 2020 07h00 HE | Jounce Therapeutics, Inc.
- No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis- - First patient dosed in SELECT trial of vopratelimab in combination with JTX-4014 in...
jounce.png
Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Friday, November 6, 2020
30 oct. 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September
02 sept. 2020 16h01 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
01 sept. 2020 08h30 HE | Jounce Therapeutics, Inc.
  – Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead to Make $85 Million Upfront Payment and $35 Million Equity Investment – FOSTER CITY, Calif. and...
jounce.png
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
07 août 2020 06h30 HE | Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...